FDA OKs New Option for Difficult to Treat, Rare Form of Childhood Leukemia


84
18 shares, 84 points

CANCER HEALTH

Cover picture for the article

The Food and Drug Administration (FDA) recently approved azacitidine (Vidaza) for pediatric patients 1 month and older with newly diagnosed juvenile myelomonocytic leukemia (JMML). JMML is an uncommon blood cancer that accounts for 1–2% of all childhood leukemia cases and most often occurs in infants and children younger than…

www.cancerhealth.com Read more – CANCER HEALTH

Advertisements

Like it? Share with your friends!

84
18 shares, 84 points

What's Your Reaction?

hate hate
8
hate
confused confused
1
confused
fail fail
13
fail
fun fun
11
fun
geeky geeky
10
geeky
love love
5
love
lol lol
6
lol
omg omg
1
omg
win win
13
win